‘Fierce new drugs,’ Belviq and Xtandi, reserved to be blockbusters
Recently-launched new products have shown smooth starts. In particular, Belviq, an obesity treatment, and ‘Xtandi,’ a prostate cancer treatment, have already notified the market of becoming KRW 10 billion blockbusters.
According to the Medipana News’s analysis result of sales performance of rece...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
